Madrigal Pharmaceuticals (MDGL) Accounts Payables (2019 - 2025)
Historic Accounts Payables for Madrigal Pharmaceuticals (MDGL) over the last 13 years, with Q3 2025 value amounting to $44.9 million.
- Madrigal Pharmaceuticals' Accounts Payables fell 222.99% to $44.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.9 million, marking a year-over-year decrease of 222.99%. This contributed to the annual value of $43.6 million for FY2024, which is 5548.3% up from last year.
- As of Q3 2025, Madrigal Pharmaceuticals' Accounts Payables stood at $44.9 million, which was down 222.99% from $38.0 million recorded in Q2 2025.
- In the past 5 years, Madrigal Pharmaceuticals' Accounts Payables registered a high of $46.0 million during Q3 2024, and its lowest value of $1.1 million during Q2 2021.
- In the last 5 years, Madrigal Pharmaceuticals' Accounts Payables had a median value of $21.4 million in 2021 and averaged $22.8 million.
- Within the past 5 years, the most significant YoY rise in Madrigal Pharmaceuticals' Accounts Payables was 200226.16% (2021), while the steepest drop was 7867.71% (2021).
- Madrigal Pharmaceuticals' Accounts Payables (Quarter) stood at $21.4 million in 2021, then grew by 11.46% to $23.8 million in 2022, then increased by 17.67% to $28.0 million in 2023, then surged by 55.48% to $43.6 million in 2024, then rose by 3.08% to $44.9 million in 2025.
- Its Accounts Payables was $44.9 million in Q3 2025, compared to $38.0 million in Q2 2025 and $42.1 million in Q1 2025.